Trial Profile
A Randomized, Double-blinded, Placebo-controlled, Multicenter Phase III Study Comparing Bevacizumab Plus Carboplatin/Paclitaxel Versus Placebo Plus Carboplatin/Paclitaxel in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy For Advanced Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 30 Aug 2017 to 31 Jan 2018.
- 26 Jul 2017 Planned End Date changed from 1 Dec 2016 to 30 Aug 2017.